期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卡培他滨治疗70岁以上老年中晚期消化道癌42例 被引量：1

暂未订购
导出
摘要 目的:观察卡培他滨(希罗达)对老年中晚期食管癌、胃癌、结肠癌的疗效和毒副作用。方法:口服卡培他滨2500mg/(m2·d),2次/d,餐后服用14d,21d为1个周期,每2个周期治疗后评价疗效。结果:42例可评价疗效和不良反应的患者中,无完全缓解患者,部分缓解15例,稳定22例,进展5例;中位无进展生存期8.4个月;主要毒副作用为手足综合征,其他有骨髓抑制、恶心、食欲差、皮肤色素沉着及腹泻。结论:卡培他滨治疗中晚期消化道癌疗效好、毒副作用较少,老年人耐受性好。
作者 王艳 宋萍 吕洪博
机构地区 辽宁省沈阳市第四人民医院
出处 《中国当代医药》 2010年第8期40-41,共2页 China Modern Medicine
关键词 老年 食管癌 胃癌 结肠癌
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献3

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2007:57.
  • 2De Vita F,Orditura M,Matano E,et al.A hase II study of bi-weekly oxalilatin lus infusional 5-fluorouracil and folinicacid (Folfox 4) as firstline treatment of advanced gastric cancer atients[J].Br J Cancer,2005,92(9): 1644-1649.
  • 3王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学（肿瘤学分册）,2001,28(6):447-451. 被引量：73

二级参考文献16

  • 1Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 2Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 3Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 4Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 5Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 6Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 7Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 8Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 9O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.
  • 10O'Reilly SM,Moiseyenko V,Talbot DC, et al. A randomized phase Ⅱ study of Xeloda (capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy[J]. Proc Am Soc Clin Oncol, 1998,17: 627-635.

共引文献77

同被引文献14

引证文献1

二级引证文献49

中国当代医药
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部